This product includes the webinar and SAM credit


Lauren Ritterhouse MD, PhD


Susan Hsiao MD, PhD

Description:  This webinar will cover the background and rationale for the use of tumor mutational burden (TMB) as a biomarker for immunotherapy in oncology. The various biomarkers that have been evaluated for immunotherapy will be explored and a discussion of TMB’s role and use in oncology will be made. The course will cover an overview of immunotherapy drugs, targets, and tumor types for which TMB has been used as a biomarker.

Duration: 1 hr

Level of Instruction: Basic

Last day to purchase course and claim credit: December 31,2020

Maximum SAM credit available: 1.0

This webinar is part 1 of a three-part series exploring how measuring tumor mutational burden can improve patient care. If you'd like more information about the series go here

This program has been supported through an educational grant from Bristol-Myers Squibb.

How to claim credit: To earn SAM credit, all learners must watch the webinar, achieve a minimum score of 80% on the online quiz, and complete an online survey. To access the quiz, click "Submit credit" on the course homepage or click on "My Credit" on the menu to the left and then "submit credit" for the appropriate course.

This course is approved by the American Board of Pathology for 1.0 SAM credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).

SAM questions edited by: Alan Brown, MD

* You may not submit SAMs and CME/CMLE credit for the same content.

You may also be interested in:


Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Course Information
Course Date:
June 26, 2018
Course Objectives
  • Describe the clinical utilization of TMB in oncology.
  • Define TMB and the rationale for its use as a biomarker for immunotherapy in oncology.
Pre-Test for TMB: Clinical and Diagnosic Utilization in Oncology (+SAM)
Tumor Mutational Burden: Clinical and Diagnostic Utilization in Oncology
Post-Test for TMB: Clinical and Diagnostic Utilization in Oncology (+SAM)
QA Session
How to Claim SAM
Individual topic purchase: Selected
American Board of Pathology
Self-Assessment Module: 1.00
Ritterhouse (+SAM)
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00